Development of Robust and Innovative Vaccine Effectiveness
DRIVE aims at developing a governance model between public and private entities to enable a sustainable network of influenza vaccine effectiveness. This model will ensure scientific independence in the studies and full transparency, allowing different stakeholders to fulfill their needs taking into account their respective obligations and statutes. The main challenge is to reach the capacity to perform vaccine brand-specific effectiveness studies, which is agile enough to deliver the needed outputs in timely manner, and robust enough to provide results by different age and risk groups and flexible enough to utilize novel tools while at the same time aims to be sustainable. Combining these outputs, DRIVE will establish a sustainable platform for joint influenza vaccine effectiveness evaluation which will have a positive impact on European citizens public health.
The DRIVE Project has an initial budget of €10M distributed across a total of 15 partners from academic institutions, pharmaceutical companies, regulatory, SMEs and national health institutions, sponsored by the European Commission and the European pharmaceutical industry (via EFPIA) under the auspices of the Innovative Medicines Initiative Joint Undertaking (IMI JU).